



Scythian Announces Marigold's Exclusive Agreement with Jamaica's Peter Tosh Museum

May 03, 2018 08:30 ET | Source: Scythian Biosciences Corp. - <https://globenewswire.com/news-release/2018/05/03/1495958/0/en/Scythian-Announces-Marigold-s-Exclusive-Agreement-with-Jamaica-s-Peter-Tosh-Museum.html>

— ***Medicinal Cannabis Dispensary to open in Peter Tosh Square*** —

— ***Peter Tosh Square to be the home of Marigold's first herb house*** —

TORONTO, May 03, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "**Company**" or "**Scythian**") (TSXV:SCYB) (Frankfurt:[9SB](#)) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that Jamaica-based Marigold Projects Jamaica Ltd. ("**Marigold**"), a company that Scythian is in the process of acquiring a 49% interest in, has signed an exclusive sponsorship agreement with the world-renowned Peter Tosh Museum (the "**Museum**") in Kingston, Jamaica. Under the terms of the agreement, Marigold will become the exclusive cannabis dispensary partner of the Museum.

Marigold is set to establish its first medicinal cannabis dispensary and herb house at the Peter Tosh Square, home of the Peter Tosh Museum at the Pulse Centre in New Kingston. As the exclusive cannabis sponsor, Marigolds branding will be showcased in the world-renowned Museum.

The Museum opened its doors on October 19, 2016, and honours the life and work of Peter Tosh, Jamaica's global music legend and founding member of the critically acclaimed reggae group, The Wailers. The Museum is located at the Pulse Centre on Trafalgar Road in New Kingston and is a joint collaboration between The Peter Tosh Estate, Pulse Investments Ltd and Andrea Marlene Brown.

"We are honoured to provide the highest quality cannabis products to such a distinguished institution focused on recognizing a beloved Jamaican musician who championed the cause of legalizing cannabis," said Scythian CEO Rob Reid. "We look forward to helping his legacy live on through our commitment to furthering medical marijuana research and expanding access to cannabis in the future."

On March 22, 2018, Scythian announced that it had entered into a binding letter of intent ("**Letter of Intent**") to acquire Marigold Acquisitions Inc. ("**Holdco**"), a company that holds a 49% interest in Marigold. If the proposed acquisition is completed, Scythian will become a major stakeholder of Marigold. Marigold holds five conditional cannabis licenses from the Jamaican Cannabis Licensing Authority ("**CLA**") related to cultivation, processing, selling, therapeutic or spa services, and R&D activities. Marigold is also working with the University of West Indies to develop and test products derived from high cannabidiol cannabis sativa strains to establish their efficacy in treating diabetes, hypertension, pain and other ailments. The proposed acquisition is subject to regulatory approval from the TSX Venture Exchange ("**TSXV**"). The proposed acquisition also remains subject to notification to the CLA. The opening of the herb house remains subject to CLA approval.

About Scythian Biosciences Corp.

Scythian is a research and development company committed to advancing prevention and treatment efforts for concussion and traumatic brain injury with its proprietary cannabinoid-based combination drug therapy.

Scythian's mission is to be the first accepted drug regimen for the treatment of concussion. Scythian is partnered with the University of Miami and its neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. Through the Company's collaborative efforts with the university, Scythian has access to the university's extensive network of experts in the fields of traumatic brain injury and concussion. These connections provide Scythian with the ability to conduct its clinical studies at world-class facilities by widely recognized medical professionals.

Scythian has initiated its international expansion by launching additional cannabis-related activities across the globe. These significant endeavours complement the Company's research and development efforts to enhance the many medical applications of cannabis.

Scythian is evaluating several strategic initiatives and pursuing partnerships with local cultivators, pharmaceutical import and distribution entities and universities in North America, South America, the Caribbean and beyond. This comprehensive approach positions Scythian as a potential global frontrunner in the research and development of medical cannabis.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT INFORMATION

Scythian Biosciences Corp.

Rob Reid, CEO

Phone: (212) 729-9208

Email: info@scythianbio.com

For media inquiries, please contact:

David Schull or Nic Johnson

Russo Partners

(858) 717-2310

david.schull@russopartnersllc.com

nic.johnson@russopartnersllc.com